MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.907
AS - Asia 8.681
EU - Europa 8.289
SA - Sud America 1.112
OC - Oceania 539
AF - Africa 414
Continente sconosciuto - Info sul continente non disponibili 13
Totale 36.955
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.287
GB - Regno Unito 2.959
SG - Singapore 1.919
CN - Cina 1.671
IT - Italia 1.062
HK - Hong Kong 904
VN - Vietnam 866
DE - Germania 843
BR - Brasile 790
SE - Svezia 632
PH - Filippine 551
AU - Australia 494
TR - Turchia 467
FI - Finlandia 446
FR - Francia 437
CA - Canada 433
RU - Federazione Russa 340
UA - Ucraina 287
IR - Iran 286
IN - India 285
KR - Corea 204
PK - Pakistan 190
ID - Indonesia 161
JP - Giappone 147
NL - Olanda 141
IE - Irlanda 139
BG - Bulgaria 119
MY - Malesia 117
PL - Polonia 116
BD - Bangladesh 115
ES - Italia 115
ZA - Sudafrica 113
AR - Argentina 108
GR - Grecia 99
MX - Messico 98
SA - Arabia Saudita 93
IQ - Iraq 87
IL - Israele 85
TW - Taiwan 85
MA - Marocco 77
BE - Belgio 71
AT - Austria 64
TH - Thailandia 59
AE - Emirati Arabi Uniti 57
NP - Nepal 55
EC - Ecuador 50
RO - Romania 49
LK - Sri Lanka 45
CO - Colombia 44
KE - Kenya 44
NZ - Nuova Zelanda 44
JO - Giordania 43
NO - Norvegia 42
GE - Georgia 39
EG - Egitto 38
CH - Svizzera 35
LT - Lituania 33
LV - Lettonia 32
CZ - Repubblica Ceca 30
CL - Cile 29
EE - Estonia 28
PT - Portogallo 28
HR - Croazia 25
NG - Nigeria 23
VE - Venezuela 22
BA - Bosnia-Erzegovina 21
TN - Tunisia 21
UZ - Uzbekistan 21
HU - Ungheria 20
PE - Perù 18
SI - Slovenia 18
DZ - Algeria 17
OM - Oman 17
PY - Paraguay 17
SK - Slovacchia (Repubblica Slovacca) 17
BO - Bolivia 14
BZ - Belize 14
UG - Uganda 14
UY - Uruguay 13
BH - Bahrain 12
LB - Libano 12
AZ - Azerbaigian 10
CY - Cipro 10
DK - Danimarca 10
DO - Repubblica Dominicana 10
ET - Etiopia 10
PR - Porto Rico 10
MU - Mauritius 9
PA - Panama 9
PS - Palestinian Territory 9
CR - Costa Rica 8
KZ - Kazakistan 8
QA - Qatar 8
JM - Giamaica 7
LY - Libia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GH - Ghana 6
GY - Guiana 6
KG - Kirghizistan 6
MO - Macao, regione amministrativa speciale della Cina 6
Totale 36.818
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Ashburn 1.629
Southend 1.619
Santa Clara 1.323
Singapore 1.221
Woodbridge 1.143
Chandler 839
Houston 826
Hong Kong 805
Seattle 686
Wilmington 658
Cambridge 591
Jacksonville 505
San Jose 441
Dearborn 428
Ann Arbor 404
Nyköping 401
Beijing 372
Hefei 370
London 339
Helsinki 332
Los Angeles 301
Ho Chi Minh City 275
Chicago 264
New York 237
Hanoi 229
Modena 228
Frankfurt am Main 224
Council Bluffs 212
Redwood City 183
Munich 180
San Diego 178
The Dalles 163
Izmir 154
Seoul 126
Shanghai 120
Princeton 116
Sofia 113
Salt Lake City 111
Melbourne 106
Dallas 104
Eugene 96
Moscow 94
Lauterbourg 88
Jakarta 81
São Paulo 81
Milan 77
Dublin 76
Manchester 75
Sydney 75
Buffalo 73
Tokyo 71
Istanbul 69
Ottawa 61
Bremen 59
Brisbane 59
Elk Grove Village 53
Warsaw 53
Bologna 50
Columbus 50
Phoenix 49
Tampa 47
Falls Church 46
Paris 46
Taipei 46
Athens 43
Liverpool 43
Johannesburg 42
Da Nang 41
Brussels 40
Montreal 40
Quezon City 39
Casablanca 38
Des Moines 38
Tehran 38
Fremont 37
Colombo 35
Karachi 35
Lahore 35
Orem 35
Riyadh 35
Toronto 35
Denver 34
Dong Ket 34
Islamabad 34
Kuala Lumpur 34
Stockholm 34
Cebu City 32
Manila 32
Perth 32
Amsterdam 31
Birmingham 31
Boston 31
Amman 30
Atlanta 30
Brooklyn 30
Davao City 30
Rio de Janeiro 30
Rome 30
Nairobi 29
Totale 23.163
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.869
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 679
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 619
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 604
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 512
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 507
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 484
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 464
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 425
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 398
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 394
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 393
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 384
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 376
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 374
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 371
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 363
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 359
Empathic attitudes among nursing students: a preliminary study 357
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 357
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 356
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 355
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 352
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 346
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 345
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 341
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 340
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 328
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 326
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 325
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 317
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 311
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 306
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 305
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 304
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 303
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 299
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 298
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 298
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 297
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 296
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 295
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 295
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 294
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 293
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 292
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 290
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 290
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 289
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 288
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 285
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 281
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 280
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 280
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 279
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 276
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 275
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 273
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 272
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 272
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 272
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 271
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 271
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 271
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 269
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 267
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 266
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 266
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 266
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 260
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 259
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 257
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 244
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 242
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 241
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 239
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 237
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 228
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 228
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 228
Twenty-years experience with de novo metastatic breast cancer 227
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 226
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 226
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 217
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 217
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 214
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 214
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 213
I tumori nelle provincie di Parma, Reggio Emilia, Modena 209
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 206
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 198
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 197
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 188
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 186
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 186
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 184
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 182
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 182
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 179
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 177
Totale 36.546
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.499
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.073 0 0 0 0 0 0 0 0 0 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/20268.945 658 424 690 1.193 1.679 785 1.181 522 959 854 0 0
Totale 37.367